PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
Nasdaq27 天
Guru Fundamental Report for PODD
Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.